Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001164161.2(PPP6R3):c.331C>A(p.Leu111Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
PPP6R3 (HGNC:1173): (protein phosphatase 6 regulatory subunit 3) Protein phosphatase regulatory subunits, such as SAPS3, modulate the activity of protein phosphatase catalytic subunits by restricting substrate specificity, recruiting substrates, and determining the intracellular localization of the holoenzyme. SAPS3 is a regulatory subunit for the protein phosphatase-6 catalytic subunit (PPP6C; MIM 612725) (Stefansson and Brautigan, 2006 [PubMed 16769727]).[supplied by OMIM, Nov 2010]
Uncertain significance, criteria provided, single submitter
clinical testing
Ambry Genetics
Jul 02, 2024
The c.331C>A (p.L111I) alteration is located in exon 4 (coding exon 2) of the PPP6R3 gene. This alteration results from a C to A substitution at nucleotide position 331, causing the leucine (L) at amino acid position 111 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Gain of catalytic residue at L116 (P = 0.0608);.;.;Gain of catalytic residue at L116 (P = 0.0608);Gain of catalytic residue at L116 (P = 0.0608);Gain of catalytic residue at L116 (P = 0.0608);Gain of catalytic residue at L116 (P = 0.0608);Gain of catalytic residue at L116 (P = 0.0608);Gain of catalytic residue at L116 (P = 0.0608);Gain of catalytic residue at L116 (P = 0.0608);Gain of catalytic residue at L116 (P = 0.0608);